HC Wainwright & Co. Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $16
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $16.
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $16.